Absci Corporation reported $1.6M of revenue over the trailing twelve months, −62% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.6M (to Q2 2026). Net income: −$121M, trailing twelve months to Q2 2026. Free cash flow: −$109M, trailing twelve months to Q2 2026. Operating margin: −9460%, trailing twelve months to Q2 2026.

ABSIAbsci Corporation

Healthcare

$10.17+289% 1Y

$10.17

$2.3052 weeks$11.53

ABSI as reported

Absci Corporation reported $1.6M of revenue over the trailing twelve months, −62% on the year before. 9 reported series are charted on this page, each one as filed.

$1.6M

Revenue, trailing twelve months · to Q2 2026 · −62% against the twelve months before

Net income: −$121M
Net income · +6.9% year on year · trailing twelve months to Q2 2026
Free cash flow: −$109M
Free cash flow · +42% year on year · trailing twelve months to Q2 2026
Operating margin: −9460%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ABSI, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.6M	−62%	Q2 2026
Net income	−$121M	+6.9%	Q2 2026
EPS	−$0.79	−17%	Q2 2026
Operating margin	−9460%	n/a	Q2 2026
Net margin	−9088%	n/a	Q2 2026
ROE	−58%	n/a	Q2 2026
ROA	−51%	n/a	Q2 2026
ROIC	−199%	n/a	Q2 2026
Free cash flow	−$109M	+42%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.